Hepato-Pancreato-Biliary tumors
Conditions
Interventions
Case series:personalized therapy based on neoantigens
Sponsors
Beijing Cancer Hospital / Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients have signed informed consent; 2. Aged between 18 and 75 years; 3. Patients who were diagnosed as initial, relapsed or metastasizd hepatocellular carcinoma, cholangiocarcinoma, or pancreatic cancer by pathology; 4. The tumor could not be treated with radical surgery resection according to the NCCN staging; 5. Patient who was under conventional chemotherapy, evaluated as SD or PD by RECIST1.1, and assessed by MDT that there wont be any clinical benefit after the conventional therapy. 6. Tumor tissue can be obtained by palliative surgical resection or needle puncture without causing uncontrollable serious complications; or paraffin-embedded tumor tissue or frozen tumor tissue within one year can be provided; 7. At least one lesion can be measured (>10 mm); 8. Enhanced CT or MRI examination can be accepted; 9. The ECOG score is 0 or 1; 10. The expected life expectancy of the patient is equal or greater than 4 months.
Exclusion criteria
Exclusion criteria: 1. The DNA QC (quality control) of the tumor tissue to be tested using whole exome sequencing(WES) does not reach the standard; 2. Neutrophil count <1.5 × 10^9/L, or hemoglobin <100g / L, or platelet count <80 × 10^9/L; 3. Bilirubin or serum creatinine is above the upper normal limit; 4. Patients with serious disease history in heart, brain, kidney, retina, muscle or other important organs or tissues; 5. Other circumstances that the investigator considered not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival;safety;Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free-Survival; | — |
Countries
China
Contacts
Public ContactChunyi Hao
Peking University Cancer Hospital
Outcome results
None listed